HEPATOBLASTOMA

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells, which are genetically modified in the lab to recognize and attack cancer cells…

This study tests a combination of three drugs—pucotenlimab (an immunotherapy), lenvatinib (a targeted therapy), and irinotecan (chemotherapy)—in 24 children aged 2-18 with advanced or relapsed hepatoblastoma that has not responded to prior treatment. The goal is to see if this mi…

This early-phase trial tests a four-drug combination—vorinostat plus three chemotherapy drugs—in children, teens, and young adults up to age 30 whose solid tumors or brain cancers have returned or not responded to standard treatment. The main goal is to find the safest dose of vo…

This early-stage trial tests a new drug called GAIA-102 in children whose neuroblastoma or other solid tumors have not responded to standard treatments. The study has four groups, testing GAIA-102 alone or combined with other cancer drugs. The main goal is to check safety and fin…

This early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…

This phase 3 trial tests whether sodium thiosulfate, given after cisplatin chemotherapy, can prevent hearing loss in children with hepatoblastoma (a rare liver cancer). About 330 children will be enrolled, some receiving the hearing-protecting drug and others not. The study also …

This study is testing a drug called patritumab deruxtecan in children whose liver or muscle cancers have returned or not responded to treatment. The drug works like a smart bomb, attaching to a protein on cancer cells to deliver a toxic payload. The trial will check if it is safe…

This early-phase trial tests a new type of immunotherapy for adults with solid tumors that have a protein called GPC3 on their surface. Researchers take a patient's own T cells, add genes to help them recognize and attack GPC3-positive cancer cells, and also include a safety swit…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This study tests a new combination of chemotherapy drugs for children and teens with hepatoblastoma, a rare liver cancer. The goal is to improve survival, especially for high-risk patients who currently have poor outcomes. About 100 participants under 18 will receive the treatmen…

This study is collecting genetic and molecular data from up to 1,600 children with liver cancer and their families. Researchers will analyze DNA, gene activity, and immune cells in tumors to better understand how these cancers develop. The goal is to improve how doctors classify …